ArticlePersonalized medicine2017
Clinical application of a cancer genomic profiling assay to guide precision medicine decisions.
Article in Personalized medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncology.Neoplasia (New York, N.Y.) · 2026Review
- Evaluation of potential of targeted sequencing through mutational signature simulation.PloS one · 2025Article
- Review
- Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.BMC cancer · 2024Article
- Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations.Journal of neuro-oncology · 2024Article
- Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.Journal of advanced research · 2023Article
- Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.Cancer medicine · 2023Article
- Profiling of host genetic alterations and intra-tumor microbiomes in colorectal cancer.Computational and structural biotechnology journal · 2021Article
- Article
- Next-generation sequencing for the general cancer patient.Clinical advances in hematology & oncology : H&O · 2019Review
- Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers.PLoS computational biology · 2019Review
- Next generation sequencing-based gene panel tests for the management of solid tumors.Cancer science · 2019Review
- Preventive, predictive, and personalized medicine for effective and affordable cancer care.The EPMA journal · 2018Review
- Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.Virchows Archiv : an international journal of pathology · 2018Article
- Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.Journal of personalized medicine · 2018Article
- Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.Cancers · 2018Review
- Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.PloS one · 2018Article
- Actionable gene alterations in an Asian population with triple-negative breast cancer.JCO precision oncology · 2018Article
- Actionable gene-based classification toward precision medicine in gastric cancer.Genome medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimDevelop and apply a comprehensive and accurate next-generation sequencing based assay to help clinicians to match oncology patients to therapies. MATERIALS &
methodsThe performance of the CANCERPLEX
resultsThe maximum sensitivity of the assay is 99.5% and its accuracy is virtually 100% for detecting somatic alterations with an allele fraction of as low as 10%. Clinically actionable variants were identified in 93% of patients (930 of 1000) who underwent testing.
conclusionThe test's capacity to determine all of the critical genetic changes, tumor mutation burden, microsatellite instability status and viral associations has important ramifications on clinical decision support strategies, including identification of patients who are likely to benefit from immune checkpoint blockage therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.